Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 Pons Pons +35.47%
#3 龙虾 (Lobster) 龙虾 (Lobster) +30.81%
#4 Rain Rain +30.63%
#5 MetaDAO MetaDAO +27.10%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +21.74%
#7 Bedrock Bedrock +20.16%
#8 Prom Prom +17.45%
#9 Ontology Gas Ontology Gas +15.41%
#10 peaq peaq +15.03%
Coin of the day
QuantixAI QuantixAI
설정
언어
한국어
통화
USD
테마
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
주식 순위 #2737
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
주가
$70.50
마지막 동기화: 2025-11-14
시가총액
$7.33B
변동 (1일)
0.00%
변동 (1년)
116.32%
국가
US
거래 Metsera, Inc. (MTSR)

카테고리

Healthcare
Metsera, Inc. (MTSR)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Metsera, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Metsera, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH